Table 1.

Patient baseline characteristics at the initiation of teclistamab

CharacteristicsFrequency
Age at diagnosis, y, median (min-max) 64 (41-78) 
Age at teclistamab therapy, y, median (min-max) 66 (43-81) 
Sex, n (%)  
Male 8 (50) 
Female 8 (50) 
Race, n (%)  
White 13 (81.25) 
Black 3 (18.75) 
Myeloma subtype, n (%)  
IgG 9 (56.25) 
IgA 3 (18.75) 
IgM 1 (6.25) 
Light chain 3 (18.75) 
High-risk cytogenetics, n (%) 16 (100) 
Triple-refractory, n (%) 15 (93.75) 
Penta-refractory, n (%) 10 (62.5) 
Number of prior lines of therapy, median (range) 4.5 (2-10) 
Prior BCMA-targeted therapy, n (%) 4 (25) 
Number of prior stem cell transplants, n (%) 
2 (12.5) 
10 (62.5) 
4 (25) 
PET scan ≥3 focal lesions, n (%) 8 (50) 
EMD, n (%) 5 (31.25) 
CPCs, %, median (range) 7.45 (5-82) 
Serum creatinine (mg/dL), median (range) 1.1 (0.6-7.0) 
Hemoglobin (g/dL), median (range) 8.6 (6.7-10.7) 
Absolute neutrophil count (× 103/μL), median (range) 1.5 (0.1-7.4) 
ALC (× 103/μL), median (range) 0.5 (0.2-6.5) 
Platelet count (× 103/μL), median (range) 28 (3-170) 
CharacteristicsFrequency
Age at diagnosis, y, median (min-max) 64 (41-78) 
Age at teclistamab therapy, y, median (min-max) 66 (43-81) 
Sex, n (%)  
Male 8 (50) 
Female 8 (50) 
Race, n (%)  
White 13 (81.25) 
Black 3 (18.75) 
Myeloma subtype, n (%)  
IgG 9 (56.25) 
IgA 3 (18.75) 
IgM 1 (6.25) 
Light chain 3 (18.75) 
High-risk cytogenetics, n (%) 16 (100) 
Triple-refractory, n (%) 15 (93.75) 
Penta-refractory, n (%) 10 (62.5) 
Number of prior lines of therapy, median (range) 4.5 (2-10) 
Prior BCMA-targeted therapy, n (%) 4 (25) 
Number of prior stem cell transplants, n (%) 
2 (12.5) 
10 (62.5) 
4 (25) 
PET scan ≥3 focal lesions, n (%) 8 (50) 
EMD, n (%) 5 (31.25) 
CPCs, %, median (range) 7.45 (5-82) 
Serum creatinine (mg/dL), median (range) 1.1 (0.6-7.0) 
Hemoglobin (g/dL), median (range) 8.6 (6.7-10.7) 
Absolute neutrophil count (× 103/μL), median (range) 1.5 (0.1-7.4) 
ALC (× 103/μL), median (range) 0.5 (0.2-6.5) 
Platelet count (× 103/μL), median (range) 28 (3-170) 

At least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody.

At least 2 proteasome inhibitors, 2 immunomodulatory drugs, and 1 anti-CD38 antibody.

or Create an Account

Close Modal
Close Modal